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Available online 16 June 2016Huntington's disease (HD) is an inherited neurodegenerative disease characterized by motor, cognitive and
psychiatric symptoms. Atrophy of the striatum has been proposed for several years as a biomarker to assess
disease progression inHDgene carriers. However, it does not provide any information about the biologicalmech-
anisms linked to HD pathogenesis. Changes in brain metabolites have been also consistently seen in HD patients
and animal models usingMagnetic Resonance Spectroscopy (MRS), but metabolite measurements are generally
limited to a single voxel. In this study, we used Chemical Exchange Saturation Transfer imaging of glutamate
(gluCEST) in order to map glutamate distribution in the brain of a knock-in mouse model (Ki140CAG) with a
precise anatomical resolution. We demonstrated that both heterozygous and homozygous mice with patholog-
ical CAG repeat expansion in gene encoding huntingtin exhibited an atrophy of the striatum and a signiﬁcant
alteration of their metabolic proﬁle in the striatum as compared to wild type littermate controls. The striatal de-
crease was then conﬁrmed by gluCEST imaging. Surprisingly, CEST imaging also revealed that the corpus
callosumwas themost affected structure in both genotype groups, suggesting that this structure could be highly
vulnerable in HD. We evaluated for the ﬁrst time gluCEST imaging as a potential biomarker of HD and demon-
strated its potential for characterizing metabolic defects in neurodegenerative diseases in speciﬁc regions.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Huntington's disease (HD) is an inherited neurodegenerative
disorder characterized by involuntary abnormal movements, as well
as cognitive and psychiatric symptoms associated with early atrophy
of the striatum and cerebral cortex (Harper, 1991; Walker, 2007). The
mutation causingHD consists of an abnormal expansion of a CAG repeat
in the gene coding the protein huntingtin (htt). There is no therapy to
slow the progression of the disease which is fatal in 10–15 years after
the onset of symptoms in young individuals. Despite active research in
the past twenty years, the mechanisms underlying brain dysfunction
and degeneration remain poorly understood. Mutation of huntingtin
affects many cellular processes such as transcription (Sugars and
Rubinsztein, 2003), neurotransmission, calcium homeostasis (Cowan
and Raymond, 2006), autophagy and energy metabolism (Bossy et al.,ma— BP n° 6, 92265 Fontenay-
. This is an open access article under2008; Damiano et al., 2010; Mochel et al., 2007; Mochel and Haller,
2011) in both neurons and astrocytes.
There is a limited number of methods allowing precise follow up of
disease progression andunderstanding of physiopathological pathways.
Clinical assessments along with neuroimaging techniques are likely the
most robust criteria to characterize disease severity in HD patients. For
instance, the atrophy of the striatum as measured by MRI is currently
the best biomarker of disease progression in HD gene carriers
(Aylward et al., 2004; Paulsen et al., 2008; Tabrizi et al., 2013). However,
although anatomical alterations seen by MRI can be found many years
before onset of symptoms in HD gene carriers, they do not provide
any information about the biological mechanisms linked to HD patho-
genesis. In the case of clinical trials, morphometric MRI might be crucial
to determine whether the therapy modiﬁes or slows down atrophy but
does not give rapid indication about biological efﬁcacy of the treatment.
Thus, there is a need to develop novel “functional” imaging modalities.
Defects in brain energy metabolism have been consistently found in
HD patients and animal models. In particular, Positron Emission
Tomography (PET) studies demonstrated large reduction in glucose
consumption in the caudate/putamen in HD patients (Brouillet et al.,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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methods to more broadly characterize energy metabolism in HD are
rare. In vivo Magnetic Resonance Spectroscopy (MRS) can provide key
insights of pathological molecular processes related to cell metabolism.
Analysis of human HD cohorts or transgenic mouse models of HD using
in vivo 1H or 31PMRSmethods suggested earlymetabolic changes in the
brain (Jenkins et al., 1998; Mochel et al., 2012; Sturrock et al., 2010;
Zacharoff et al., 2012). Interestingly, several studies using 1H MRS
showed that the concentrations of glutamate and N-acetyl-aspartate,
two metabolites mainly located in neurons, were decreased in HD
patients and animal models (Jenkins et al., 1998, 2000, 2005).
Glutamate is the major excitatory transmitter in the central nervous
system and is involved in several aspects of normal brain functions
including cognition, memory and learning. Its concentration in the
brain is higher than all other amino acids (around 10 mmol/kg), and
it plays a central role in brainmetabolism (Sonnewald, 2014). Regulato-
ry system of glutamate concentration in the brain is very complex
(Magistretti and Allaman, 2015). In normal conditions, most of gluta-
mate is located in cells, neurotransmission being governed by few
micromolar of extracellular glutamate. Glutamate can become toxic
if extracellular concentration is too high. In such case, glutamate
overactivates ionotropic glutamate receptors, and producing major
rise in Ca2+ concentration in the cytoplasm of neurons, triggers
excitotoxicity (Beal, 2005; Brouillet et al., 1999; Cowan and Raymond,
2006). Thus, mechanisms to maintain low extracellular concentration
are crucial for brain functions. In addition to its major role as an excit-
atory neurotransmitter, glutamate is central to several metabolic
pathways related to energy metabolism and oxidative stress. For
instance, it is involved in many crucial biological pathways such as the
tricarboxylic acid (TCA) cycle (it is in exchange with TCA cycle interme-
diate alpha-ketoglutarate), regulation of glutathione synthesis and as-
trocyte–neuron interactions. Consequently, glutamate concentration
has to be precisely regulated and a small defect can be very deleterious
for the brain.
In this context, 1H MRS has been widely used to precisely monitor
alterations of metabolic proﬁles and particularly glutamate concentra-
tion. However, one important limitation of MRS is that glutamate
measurements are conﬁned to relatively large voxels, due to limited
sensitivity of the method. Thus, it would be of major interest to ﬁnd
functional biomarkers related to energy metabolism that could be
monitored in the entire brain and with good anatomical resolution in
HD animal models or gene carriers. Recently, CEST (Chemical Exchange
Saturation Transfer) has been proposed to indirectly detect dilute
molecules with labile protons (Ward et al., 2000; Ward and Balaban,
2000; Wolff and Balaban, 1990). Exchangeable protons, for example
amine (−NH2) or amide (−NH) groups, exhibit a resonance frequency
that is shifted relative to bulk proton frequency. Likewise, exchangeable
protons can be selectively saturated using radiofrequency (RF) pulse,
leading to a decrease of water signal due to magnetization exchange.
The potential of CEST imaging to map glutamate level has already
been demonstrated in both rodent and human brains at high magnetic
ﬁelds (≥7 T) (Cai et al., 2012, 2013; Carrillo-de Sauvage et al., 2015). It
is thus possible to map local alteration in glutamate concentrations,
which may be a potential indicator of regional energy defects in vivo.
Here, we investigated whether gluCEST could represent a relevant
biomarker of HD. To do so, we studied a knock-in (Ki) mouse model
of HD. Several Ki mouse models have already been described in the
literature expressing various length of CAG triplet, from 50 to 175 (Lin
et al., 2001; Menalled, 2005; Wheeler et al., 2002). These Ki mice
are usually characterized by the slowly progressive appearance of the
symptoms, which mimics more closely human HD pathology than
severe and rapid mouse models (Lin et al., 2001; Menalled and
Chesselet, 2002; Menalled et al., 2003; Wheeler et al., 2000). In the
present study, we developed and applied gluCEST imaging to examine
brain glutamate concentrations in a slowly progressing mouse model
of HD, the Kimice expressing chimericmouse/human exon1 containing140CAG repeats inserted in themurineHtt gene (Ki140CAG) (Menalled
et al., 2003).
Materials and methods
Ki140CAG and wild type littermate mice
Mice were housed in a temperature-controlled roommaintained on
a 12 h light/dark cycle. Food and water were available ad libitum. All
animal studies were conducted according to the French regulation (EU
Directive 2010/63/EU — French Act Rural Code R 214-87 to 131).
The animal facility was approved by veterinarian inspectors (authoriza-
tion n° A 92-032-02) and complies with Standards for Humane Care
and Use of Laboratory Animals of the Ofﬁce of Laboratory Animal
Welfare (OLAW — n°#A5826-01). All procedures received approval
from the ethical committee (authorization n°2015060417243726vl
(APAFIS#770).
In the present study, we used knock-in mice expressing chimeric
mouse/human exon 1 containing 140 CAG repeats inserted in the
murine Htt gene (Ki140CAG). Ki140CAG mice colony was maintained
by breeding heterozygotes Ki140CAG males and females (Menalled
et al., 2003). Mice were N3 (B6) on a 129 Sv × C57BL/6J background.
Genotype was determined from PCR of tail snips taken at 10–15 days
of age for Ki140CAGmice. The resultingmice of our colonywere divided
in 2 groups depending on their genotype; heterozygous and homozy-
gous for the Htt gene. Ki140CAG mice were compared to their wild
type (WT) littermate controls.
Preliminary behavioral testing of the Ki140CAG mouse colony
Open-ﬁeld test
We used groups of WT (n = 3, 3 females), heterozygous (n = 5, 3
females, 2 males), and homozygous (n = 8, 5 females, 3 males) mice.
The three groups of 7–15 month-old mice were matched for age
(mean ± SEM in months: WT, 9.33 ± 1.86; heterozygous, 11.10 ±
2.68; homozygous, 11.81 ± 0.72) and were not statistically different
in body weight (mean ± SEM in grams: WT, 27.30 ± 0.51; heterozy-
gous, 29.05± 2.9; homozygous 26.47± 1.21). We assessed the sponta-
neous locomotor activity of Ki140CAGmice in an automated Ethovision
XT/open-ﬁeld apparatus (Noldus). Mice were transferred to the testing
room and allowed to acclimate for at least 30 min before testing. The
open-ﬁeld consisted of a square arena (50 × 50 cm, 40 cm high). The
ﬂoor was divided into two virtual concentric parts, with an inner zone
in the middle of the arena (25 × 25 cm) and an outer zone extending
from the outer edge of the inner zone to the walls of the structure.
Animalswere placed in the center of the arena at the start of the test. Lo-
comotor activity was monitored for 10 min with a video camera
mounted on the ceiling directly above the center of the arena. The
ﬂoor of the arena was washed with 70% ethanol between tests, to
remove the odor of the previous subject. A computerized tracking
system (Ethovision XT, Noldus IT) calculated total locomotion, speed,
and time spent immobile by image analysis. We also recorded duration
of rearing and grooming behavior during the 10 min trial by visual
inspection of the behavior of each animal using time encoded video re-
cording (the Observer, Noldus).
Rotarod test
We used groups of WT (n = 5, 4 females, 1 male), heterozygous
(n = 9, 1 female, 8 males), and homozygous (n = 10, 4 females, 6
males) mice. Mice were different from those used for the open-ﬁeld
test. The three groups of 10–13 month-old mice were matched for age
(mean ± SEM in months: WT, 10.60 ± 1.03; heterozygous, 11.10 ±
0.33; homozygous, 11.50 ± 0.52) and were not statistically different
in body weight (mean ± SEM in grams: WT, 28.22 ± 0.79; heterozy-
gous, 28.03 ± 0.74; homozygous 26.27 ± 0.83). The rotarod test was
used to evaluate the motor coordination and strength of the mice.
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tions per minute (rpm) for 5 min. They were then tested in three
consecutive trials, each lasting 5 min, in which the speed of the rod
was increased from 4 to 40 rpm. Mice were allowed to recover for
45 min between trials. The latency to fall (in second) in the three trials
was recorded for each mouse. Values were averaged across all trials.
This sequence was repeated on three consecutive days.
Immunohistochemistry
Mice received a lethal dose of sodium pentobarbital solution (50 μg
per gram body weight, intraperitoneal). The brain of the animals were
removed, left-hemisphere was post-ﬁxed overnight in 4% PFA in
phosphate buffer (PB) solution, then cryoprotected by immersion in
30% sucrose for 36 h. Free-ﬂoating 30-μm serial coronal sections
throughout the striatum were collected serially (interspace, 240 μm),
with a freezing sliding microtome (SM2400; Leica Microsystems,
Wetzlar, Germany). Brain slices were placed in a storage solution (30%
glycerol, 30% ethylene glycol in 0.1 M PB) and stored at−20 °C before
use. Brain slices were pretreated in 0.3% H2O2, blocked in 4.5% NGS
(Sigma), and incubated for 48 h at 4 °Cwith primary antibodies directed
against NeuN (1:2000, mouse; Millipore) or EM48 (1:200, mouse;
Millipore). After rinsing, brain slices were incubated with biotinylated
secondary anti-mouse antibody (1:1000; Vector Laboratories) for 1 h
at room temperature. Finally, they were incubated with the Vectastain
Elite ABC Kit (Vector Laboratories) and revealed with the DAB kit
(Vector Laboratories).
Anatomical MRI and proton magnetic resonance spectroscopy (1H MRS)
High resolution MRI and 1H MRS experiments were performed on a
horizontal 11.7 T Bruker scanner (Bruker, Ettlinger, Germany).We used
groups of 12-month-old WT (n = 5, 5 males), heterozygous (n = 5, 4
females, 1 male), and homozygous (n = 5, 4 females, 1 male) mice.
Mice were different from those used for behavioral tests. Mice were
anesthetized using 3% isoﬂurane in a 1:1 gas mixture of air/O2 and
positioned in a dedicated stereotaxic frame with mouth and ear bars
to prevent any movements during MR acquisitions. Mice temperature
was monitored with an endorectal probe and maintained at 37 °C
with regulated water ﬂow and respiratory rate was continuously
monitored using PC SAM software (Small Animal Instruments, Inc.,
Stony Brook, NY, USA) during scanning. The isoﬂurane level was adjust-
ed around 1.5% to keep the respiratory rate in the range of 60 to 80
per minute. A quadrature cryoprobe (Bruker, Ettlinger, Germany) was
used for radiofrequency transmission and reception. High resolution
anatomical T2-weighted images acquiredwithMulti SlicesMulti Echoes
(MSME) sequence (TE/TR = 5/2500 ms, 17 echoes, effective TE =
45 ms, in-plane resolution = 70 × 70 μm2, 25 slices with thickness =
300 μm) in coronal orientation were used for accurate delineation
of structures. The same high resolution images were used to accurately
position a voxel of 2 × 2 × 2mm3 in the left striatum. The homogeneity
of the magnetic ﬁeld was performed using Bruker MAPSHIM
routine and good shimming was reached in the voxel (between 10.5
and 15 Hz). 1H MRS acquisitions were performed using a LASER (Local-
ization by Adiabatic Selective Refocusing) sequence (echo time (TE)/
repetition time (TR) = 20/5000 ms combined with VAPOR water
suppression. Metabolites spectra were acquired using 128 repetitions
for a total scan time of 10 min. Metabolite concentrations were
quantiﬁed using LCModel (Provencher, 1993) and the macromolecule
(MM) spectrum of a control mouse was determined by metabolite
nulling and included in the base set for LCModel. The following
metabolites were reliably quantiﬁed (Cramér-Rao lower bound
(CRLB) b 5% in all experiments): total choline (glycerophosphocholine
+ phosphocholine + choline, tCho), total creatine (creatine +
phosphocreatine, tCr), glutamate (Glu), glutamine (Gln), myo-inositol
(Ins), total N-acetyl-aspartate + N-acetyl-aspartyl-glutamate(NAA + NAAG, tNAA) and taurine (Tau). Metabolite concentrations
were normalized with respect to 8 mM tCr.
Chemical Exchange Saturation Transfer imaging of glutamate (gluCEST)
GluCEST was performed on the same magnet with a volume coil for
radiofrequency transmission and a quadrature surface coil for reception
(Bruker, Ettlinger, Germany). Three gluCEST images centered on the
mid-striatumwere acquired with a 2D fast spin-echo sequence preced-
ed by a frequency-selective continuous wave saturation pulse
(150 × 150 μm2 in-plane resolution, 0.6 mm slice thickness, echo
time = 6 ms, repetition time = 5000 ms, 10 echoes and effective echo
time = 30 ms). The MAPSHIM routine was applied in a voxel
encompassing the slices of interest in order to reach a good shim on
gluCEST images. GluCEST images were acquired with a saturation
pulse applied during Tsat = 1 s, composed by 10 broad pulse of
100ms,with 20 μs inter-delay and an amplitude B1=5 μT. The frequen-
cy of the saturation pulse Δω was applied in a range from−5 ppm to
5 ppm with a step of 0.5 ppm. A set of CEST images was also acquired
with a weak saturation amplitude (B1 = 0.2 μT) around the water
frequency (Δω in a range from −1 ppm to 1 ppm with a step of
0.1 ppm) in order to correct for B0 inhomogeneities using the Water
Saturation Shift Reference (WASSR) method (Kim et al., 2009). Before
gluCEST protocol, a B1 mapwas acquired with the double angle method
(Stollberger and Wach, 1996). Two images with long repetition time
(TR = 15.000 ms) were acquired with preparation pulses ﬂip angles
of either 30° or 60°. The samenormalizationmethod, using RF pulse am-
plitude for a ﬂip angle of 30° (B1ref), as proposed in the literature was
used to calculate relative B1 map (B1/B1ref, unitless) (Cai et al., 2012).
In vivo, CEST contrast can be hampered by several competing factors
such as direct saturation transfer (DS) of free water and background
magnetization transfer (MT). Although DS is symmetrical with respect
to water frequency and its contribution to CEST contrast can be
suppressed by asymmetrical analysis (van Zijl and Yadav, 2011; Zhou
and van Zijl, 2006), it is not always the case forMT background. Howev-
er, it has been shown that MT asymmetry was minimized with high
saturation amplitude (Sun et al., 2005), which is the case for gluCEST
imaging (B1 = 5 μT).
Data processing and statistical analyses
All image processing and analyses were performed using in-house
programs developed on MATLAB software (MathWorks Inc., Natick,
MA). Striatumwasmanually delineated slice-by-slice by a single opera-
tor using high resolution images and volume was calculated for each
animal.
CEST images were processed pixel-by-pixel and analyzed using in-
house programs developed on MATLAB software used to generate Z-
spectra by plotting the longitudinal magnetization as a function of
saturation frequency. WASSR method was used to generate absolute
B0 map by ﬁnding the actual frequency within each voxel. Z-spectrum
in each voxel was interpolated using a cubic spline and B0 map
was used to correct for B0 inhomogeneities. The speciﬁc glutamate
contribution was isolated using Asymmetrical Magnetization
Transfer Ratio (MTRasym) (Liu et al., 2010) and was calculated as
follows: MTRasym(Δω) = 100 × (Msat(−Δω) − Msat(+Δω)) /
Msat(−5 ppm), Msat(±Δω) being the magnetization acquired with
saturation pulse applied at ‘+’ or ‘−’ Δω ppm. GluCEST images were
calculated with Δω centered at ±3 ppm. In order to perform regional
analysis of gluCEST contrast, several Regions of Interest (ROIs)
weremanually drawnwith help of theAllenmouse brain atlas. Segmen-
tationwas performed slice-by-slice by a single operator using the refer-
ence CEST image acquired without saturation. Variation of gluCEST
contrast between WT littermates vs. heterozygous mice or between
WT littermates vs. homozygous mice was calculated in each ROI as
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Statistical analyses were performed using Statistica (StatSoft, Inc.,
Tulsa, OK, USA) software. Mean and standard error of the mean of all
measures are reported in mean ± SEM format throughout. The
Shapiro–Wilk test was used to test the data for normality and no devia-
tion from normality was observed for any data. One-way ANOVA
(factorial) was used to compare mean values (striatal volume, metabo-
lite ratiosmeasured by 1HMRS, gluCEST contrast and open-ﬁeld data) of
each genotype groups. For the analysis of the rotarod data, one-way
ANOVA with repeated measures (days 1, 2 and 3) was used. The signif-
icant threshold was set to 0.05. ANOVAwas followed by a Fisher's Least
Signiﬁcant Difference (LSD) post-hoc test to determine individual
signiﬁcant differences between groups.Fig. 1. Behavioral and histological characterization of Ki140CAG mouse colony. a) Rotarod te
heterozygous and homozygous mice (blue, green and red curves respectively, mean ± SEM
(repeated measures over days 1, 2 and 3, signiﬁcant threshold set to 0.05) with Fisher's LS
evaluate locomotor activity of WT littermate controls, heterozygous and homozygous mice (w
time (b), grooming time (c) and distanced travelled (d). Statistical analysis was performed b
post-hoc test (***p b 0.001; **p b 0.01; *p b 0.05). e) Representative images of immunostainin
and NeuN (neurons, bottom panel). Scale bar: small panels = 20 μm; large panels = 250 μm fResults
Behavioral tests and histology
In the rotarod test, both heterozygous and homozygous mice
showed signiﬁcantly poorer performance than WT littermates
(Fig. 1.a, green and red lines respectively). Homozygous and hetero-
zygous mice appeared similarly affected when comparing the laten-
cy to fall (approximately 35% reduction) with that of WT littermates
(heterozygous, p b 0.0001; homozygous, p b 0.006).
In the open-ﬁeld, locomotor behavior was characterized by the
duration of the rearing behavior, the duration of grooming behavior
and the total distance travelled during the trials (Fig. 1.b, c and d
respectively). Both heterozygous and homozygousmice showed poorerst was used to evaluate the motor coordination and strength of WT littermate controls,
, n = 5, 9 and 10 respectively). Statistical analysis was performed by one-way ANOVA
D post-hoc test (***p b 0.001; **p b 0.01; *p b 0.05). b–d) Open-ﬁeld test was used to
hite, gray and black bars respectively, mean ± SEM, n= 3, 5 and 8 respectively): rearing
y one-way ANOVA (factorial analysis, signiﬁcant threshold set to 0.05) with Fisher's LSD
g for EM48 (mutant huntingtin-containing inclusions, zoom in the black box, top panel)
or Em48 and 400 μm for NeuN images.
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the total distance moved were reduced (Fig. 1.b and d respectively)
while grooming behavior was increased (Fig. 1.c). Statistical analysis
showed that homozygous mice were signiﬁcantly different from WT
littermates (rearing duration, p b 0.003; grooming duration, p b 0.05;
distance moved, p b 0.02) while there was only a trend in heterozygous
mice.
We also checked that the Ki140CAG mice of our colony had
huntingtin-containing aggregates, a hallmark of the pathology in HD
patients. Consistent with pioneering observations (Menalled et al.,
2003),we observed numerousmutant huntingtin-containing inclusions
in striatum and cerebral cortex of adult Ki140CAG mice. Qualitatively,
homozygous mice displayed a much higher density of inclusions as
compared to heterozygous mice (Fig. 1.e, top panel). Qualitative analy-
sis of sections stained for NeuN immunohistochemistry, a neuronal
marker, neither indicatedmajor neuronal loss normajor striatal atrophy
in Ki140CAG mice when compared to WT littermates (Fig. 1.e, bottom
panel).
Striatal volume by MRI
Previous studies have already demonstrated that brain atrophy can
occur several years before disease onset in HD gene carriers or early in
rodent HD models (Boussicault et al., 2014; Lerch et al., 2008; Rocher
et al., 2016; Sawiak et al., 2009). Among all structures known to degen-
erate in HD, the striatum is probably the most affected and its volume
has been proposed as a reliable biomarker of HD progression (Hobbs
et al., 2010; Paulsen et al., 2008). In this study, we measured the stria-
tum volume of all mice in order to document brain alteration in
Ki140CAGmice at 12month of age. The mean striatal volume of WT lit-
termates, heterozygous and homozygous mice were respectively
18.7 ± 0.7 mm3, 16.8 ± 0.7 mm3 and 14.8 ± 0.8 mm3 (Fig. 2, white,
gray and black bars respectively). Homozygous mice exhibited a
signiﬁcant 20.9% decrease of striatal volume compare toWT littermates
(p= 0.002) whereas the decrease was not signiﬁcant in heterozygous
group in spite of a trend to striatum atrophy (−10.1%, p= 0.11).
1H MRS
Raw spectra acquired with the cryoprobe in the left striatum of one
mouse of each group are shown in Fig. 3 (WTmouse: left panel; hetero-
zygous mouse: middle panel; homozygous mouse: right panel). The
metabolic proﬁles acquired in WT littermates, heterozygous and
homozygous mice groups are shown in Fig. 4 (white, gray and blackFig. 2. Striatal atrophymeasured byMRI. Striatumvolumewasmeasured inWT littermate
controls, heterozygous and homozygous mice (white, gray and black bars respectively,
mean ± SEM, n = 5 for each group). Statistical analysis was performed by one-way
ANOVA (signiﬁcant threshold set to 0.05) with Fisher's LSD post-hoc test (**p b 0.01).bars respectively). The most striking changes were decreases of Tau
and tNAA metabolites in both HD mice groups. Tau exhibited a signiﬁ-
cant−25.9% decrease (p = 0.003) and a signiﬁcant−33.3% decrease
(p=0.0002) in heterozygous and homozygous Ki140CAGmice respec-
tively and tNAA exhibited a signiﬁcant−17.4% decrease (p = 0.009)
and a signiﬁcant−24.3% decrease (p = 0.0007) in heterozygous and
homozygous Ki140CAG mice respectively. A signiﬁcant −13.0%
decrease (p = 0.03) of Glu was also seen in heterozygous Ki140CAG
mice. In homozygous mice, Glu concentrations were reduced by
−14.9% but this did not reach statistical signiﬁcance (p=0.06). Finally,
we measured a signiﬁcant 27.4% (p = 0.01) increase of Gln and a
signiﬁcant−21.7% (p = 0.03) decrease of tCho in homozygous mice.
The same trends were observed in heterozygous mice but they did not
reach statistical signiﬁcance.
GluCEST
An example of gluCEST images acquired at three slice positions in
each group of mice and corresponding z-spectrum and MTRasym are
shown in Fig. 5. The gluCEST contrast was comparable throughout
the three slices (Fig. 5.a). The gluCEST maps from Ki140CAG mice
exhibited decreased gluCEST contrast across the whole brain, reﬂecting
a decrease of glutamate concentration. The decrease of gluCEST
contrast in heterozygous mice seemed to be smaller than that in homo-
zygous (Fig. 5.a). The mean B0 shift (0.03 ± 0.03 ppm, Fig. 5.b) and
ratio B1/B1ref (0.99±0.02, Fig. 5.c)measured into imaging slices showed
the rather good homogeneity of B0 and B1 ﬁelds through the brain. A ROI
was drawnmanually in the striatum of eachmouse and the z-spectrum
andAsymmetricalMagnetization Transfer Ratio (MTRasym) curvewere
obtained for these mice (Fig. 5.d and e respectively). Z-spectra and
MTRasym conﬁrmed the more intense gluCEST contrast in the WT
littermate mouse compare to heterozygous or homozygous mice
(Fig. 5.d and e, blue, red and green lines respectively). Mean MTRasym
of WT littermates, heterozygous and homozygous mice groups were
calculated in the striatum (Fig. 6.a, blue, red and green lines respective-
ly) and in the corpus callosum (Fig. 6.b, blue, red and green lines respec-
tively). Mean MTRasym curves calculated for each group of mice
conﬁrmed the lower gluCEST contrast in homozygous mice observed
on individual images. They also conﬁrmed the intermediate gluCEST
contrast level in heterozygous mice. Moreover, one can observe that
gluCEST contrast at 3 ppm was approximately 20% higher in striatum
(mostly gray matter, GM) than in corpus callosum (white matter,
WM). This result is consistent with previous gluCEST studies showing
higher gluCEST contrast in GM than in WM due to higher glutamate
concentrations in GM (Cai et al., 2012, 2013).
In order to perform regional analysis of gluCEST contrast, several Re-
gions of Interest (ROIs)weremanually drawn based on the T2-weighted
reference image. The following structures were delineated: striatum,
corpus callosum, motor cortex, piriform cortex, septal nuclei, somato-
sensory cortex, hypothalamus and substantia innominata (Fig. 7, top
panel). Variations of mean gluCEST contrast (expressed in percentage)
measured in each ROI were calculated between control WT littermates
vs. heterozygousmice and between controlWT littermates vs. homozy-
gous mice and reported on a “variation map of gluCEST contrast” for
each group of mice (Fig. 7 bottom left and right maps respectively).
These variations and corresponding p-values are also given in Table 1.
These maps clearly evidenced the existence of differential reductions
of Glu in different regions of the brain. They also underscored a “gene-
dose” effect; the decrease of glutamate throughout the brain being
milder in heterozygous mice than in homozygous mice. The decrease
of gluCEST contrast measured in left and right striatum of homozygous
mice was signiﬁcant (−10.7% (p = 0.040) and −12.7% (p = 0.056)
respectively) whereas it did not reach statistical signiﬁcance for
heterozygous mice. Pronounced decreases of gluCEST contrast were
also measured in left and right piriform cortices (−11.0% (p= 0.078)
and−14.0% (p = 0.015) respectively) in homozygous mice whereas
Fig. 3. 1H MRS of WT littermate and Ki140CAGmice. Examples of 1H-spectrum acquired in a voxel of 8 μL located in the left striatum of one mouse of each group (WT littermate control
mouse: left panel; heterozygous mouse: middle panel; homozygous mouse: right panel). Inset: coronal image centered on mouse striatumwith the VOI delimited by the white box. The
following metabolites, total choline (tCho), total creatine (tCr), glutamate (Glu), glutamine (Gln), myo-inositol (Ins), total N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (tNAA) and
taurine (Tau), were reliably quantiﬁed (CRLB b5%).
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Surprisingly, the most affected structure in both heterozygous and ho-
mozygous mice was the corpus callosum (−21.8% (p-value = 0.033)
and−28.4% (p-value = 0.030) respectively). Interestingly, variations
of gluCEST contrasts were consistent between both hemispheres,
strongly supporting the idea that measured structure-dependent
changes were not related to random inter-regional changes due to an
inaccuracy of measurements, but to actual glutamate alterations
between brain regions.
Discussion
Behavioral and histological characterization of Ki140CAG mice
In this study,we used a knock-inmousemodel of HDwhichprovides
a genetically accurate reproduction of the human pathology. This
genetic model of HD has already been characterized by slow
progression of symptoms as deﬁcits in locomotor performances,
behavioral, cellular and molecular abnormalities and neurodegenera-
tion (Menalled et al., 2003).
The behavioral results obtained in the present study showed that
both heterozygous and homozygous adult mice exhibited poorer
performances than WT littermates. Analysis also showed that
homozygous mice seemed to be more affected than heterozygous HD
mice in the open-ﬁeld test. These results suggested that the severity of
behavioral signs is stronger in homozygous than in heterozygousFig. 4.Metabolic proﬁlesmeasured byMRS. Concentration ofmetabolites normalizedwith
respect to 8mM tCrmeasured in left striatumofWT littermate controls, heterozygous and
homozygous mice (white, gray and black bars respectively, mean ± SEM, n= 5 for each
group). Statistical analysis was performed by one-way ANOVA (signiﬁcant threshold set
to 0.05) with Fisher's LSD post-hoc test (***p b 0.001; **p b 0.01; *p b 0.05).mice, even if difference between heterozygous and homozygous mice
did not reach statistical signiﬁcance because of the small size of mice
cohorts. In the rotarod test, both heterozygous and homozygous mice
showed poorer performance than WT littermate controls. In this case,
homozygous and heterozygous mice appeared similarly affected
when comparing the “time to fall” readout. Thus, the notion that homo-
zygous mice are “behaviorally” more affected than heterozygous de-
pends on the test considered. Further characterization and larger
animal cohorts are required to fully address this question. However,
the qualitative histological evaluation with the EM48 antibody that rec-
ognizes huntingtin-positive aggregates showed that homozygous mice
hadmore inclusions than heterozygousmice, supporting the hypothesis
that homozygous mice are more affected from a molecular point of
view. This is consistent with our recent observations that reduction in
the expression of striatal markers (e.g. DARPP-32, Crym, Abdh11os) is
more pronounced in homozygous Ki140CAGmice than in heterozygous
(Francelle et al., 2015a,b). The present MRS and MRI data support this
view, even though we examined relatively small groups of WT litter-
mates and Ki140CAG mice.
Assessing HD in mice using traditional markers
We measured striatum volume of each mouse using manual
segmentation of the brain on anatomical images. These morphometric
measures demonstrated atrophy of the striatum in both groups of HD
mice. Moreover, the decrease of striatal volume of homozygous mice
was two times higher than in heterozygous mice compared to their
WT littermates. At 12 months of age, striatal volume appears to be
correlated with disease severity, as conﬁrmed by behavioral and histo-
logical characterization. This is the ﬁrst time that a signiﬁcant atrophy
of the striatum is detected by MRI in Ki140CAG mice. This model has
been examined by quantitative histological evaluation (stereological
cell counts) and no cell loss has been found in the striatum at
12 month of age (Menalled et al., 2003). Our results further support
the view that striatal atrophy, even if limited, can occur relatively
early. This is consistent with previous studies where striatal volume
was shown to be a prodromal marker of HD changes in both HD gene
carriers and other animal models and atrophy correlated with severity
of symptoms (Myers et al., 1988; Tabrizi et al., 2013). However, even
if striatal volume provides interesting clues about structure alterations
at macroscopic scale, physiological pathways underlying this striatal
alteration remain unknown. For this reason,we searched formore func-
tional alterations, possibly related to defects in energy metabolism and/
or neurotransmission using gluCEST imaging.
Metabolic alterations detected by 1H MRS
From the perspective of identifying relevant and early biological
markers of the disease, MRS is promising as it can provide valuable bio-
logical information occurring in vivo at cellular level (Zacharoff et al.,
Fig. 5. GluCEST imaging. a) Example of gluCEST images acquired at 3 ppm at three slice positions in each mouse groups (WT littermate control mouse: top panel images; heterozygous
mouse: middle panel images; homozygous mouse: bottom panel images). b) Representative B0 map. c) Representative relative B1 map. d) Corresponding z-spectra acquired in the stri-
atum of WT littermate, heterozygous and homozygous mice (blue, red and green lines respectively). e) Corresponding MTRasym spectra acquired in the striatum of WT littermate, het-
erozygous and homozygous mice (blue, red and green lines respectively).
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were signiﬁcantly different between each group of mice. Notably, we
measured a decrease in [Glu], [tNAA] and [Tau] and an increase in
[Gln]. The role of Tau in brain metabolism is not well known but several
functions have been proposed such as neurotransmission, osmoregula-
tion or neuroprotection (Foos and Wu, 2002; Law, 1998; Tadros et al.,
2005). Caution should be taken to interpret the decrease in [Tau]
observed in our study but it may reﬂect a potential alteration of such
regulatory processes in the brain of HD mice. Besides, it is usually
assumed that Glu and tNAA are essentially located in the neuronal com-
partment and can be considered as good neuronal markers (Gill et al.,
1989; Petroff et al., 1993; Simmons et al., 1991). The decrease of these
metabolites suggests alteration of the integrity of neurons and
potentially their functions. Indeed, mapping of tNAA distribution using
Chemical Shift Imaging (CSI) in the brain of a quinolinic acid rat
model revealed regions where tNAA levels recovered, suggesting tNAA
as a potential marker of neuronal dysfunction (Shemesh et al., 2010).
It has also been shown that decreased tNAA levels may reﬂect energy
production deﬁcit due to mitochondrial impairments (Tabrizi et al.,
2000). Indeed, we showed that in non-human primate and rodent
models where both the respiratory chain and TCA cycle was partially
blocked by the mitochondrial toxin 3-nitropropionic acid, brain NAAlevels assessed by MRS were found decreased in absence of neuronal
loss, and returned to control levels when the administration of the
neurotoxin was stopped (Dautry et al., 2000).
In our study, the decrease in [Glu] was only signiﬁcant in heterozy-
gous mice group. In homozygous mice group, one can also observe a
clear tendency to [Glu] decrease but the measurement variability and
the small size of the cohort prevented from reaching statistical signiﬁ-
cance (p= 0.061). Nonetheless, in spite of non-signiﬁcant decrease of
[Glu] in homozygous mice, the tendency of Glu to decrease argues in
favor of its potential involvement in the disease. Modiﬁcations in
glutamate concentrations could also be indicative of metabolic adapta-
tion and/or defects. Indeed, glutamate is in equilibrium with alpha-
ketoglutarate, and is thus directly linked to the Krebs cycle. Krebs
cycle defects can lead to brain [Glu] changes, as shown in non-human
primates chronically treated with the mitochondrial toxin 3NP
(Dautry et al., 1999, 2000). Concomitantly, we measured an increase
in [Gln] which is considered to be mainly located in astrocytic cells
(Brand et al., 1993). This may reﬂect a slight inﬂammation in the brain
of HD animals. Such alterations of metabolic proﬁle, with decreased
neuronal and increased astrocytic metabolites, are often observed in
neurodegenerative diseases. It could suggest an astrocyte/neuron im-
balance in energy substrate use and may be indicative of a disturbance
Fig. 6. Comparison ofMTRasymmeasured in striatumand corpus callosum. a)MTRasym spectra acquired in the striatumofWT littermates, heterozygous and homozygousmice (blue, red
and green lines respectively). b) MTRasym spectra acquired in the corpus callosum ofWT littermates, heterozygous and homozygous mice (blue, red and green lines respectively). Mean
values are reported in mean ± SEM format with n= 5 for each group.
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homeostasis between astrocytes and neurons (Choi et al., 2007).
Previous MRS studies have already been performed on several
transgenic mouse models of HD. The transgenic R6/2 mouse is consid-
ered as a severe HD model which mimics juvenile onset of HD (Tkac
et al., 2012). On the contrary, the knock-in Q111 model is a moreFig. 7. Variation maps of gluCEST contrasts in Ki140CAG mice. Mice brain was segmented in 8
littermate controls and Ki140CAG mice as follows: Variation = 100 × (MTRasym(WT)− M
contrast measured in heterozygous mice (bottom left) or in homozygous mice (bottom right)
with Fisher's LSD post-hoc test (*p b 0.05).progressive model and reproduces more closely the progression of the
disease in HDpatients (Menalled et al., 2009). This lattermodel is closer
to our Ki140CAGmodelwhich has a late onset of symptom and is slowly
progressive. Interestingly, all studies (including ours) showed an in-
crease in Gln and a decrease in tNAA (Jenkins et al., 2000; Tkac et al.,
2007), excepted in Q111 where tNAA seemed to remain unchangedROIs (top panel). Variation of gluCEST contrast was calculated in each ROI between WT
TRasym(Ki140CAG)) / MTRasym(WT). MTRasym(Ki140CAG) was either mean gluCEST
. Statistical analysis was performed by one-way ANOVA (signiﬁcant threshold set to 0.05)
Table 1
Variations of gluCEST contrasts. Variations were calculated betweenWT littermate controls and heterozygous mice (left column), betweenWT littermate controls and homozygous mice
(middle column) and between WT1 littermate controls and WT2 littermate controls (right column). Statistical analysis was performed by one-way ANOVA (signiﬁcant threshold set to
0.05) with Fisher's LSD post-hoc test.








Left striatum −0.3 0.970 −10.7 0.040 2.0 0.779
Right striatum −4.3 0.689 −12.7 0.056 2.7 0.592
Corpus callosum −21.8 0.033 −28.4 0.030 −1.0 0.879
Septal nuclei −4.8 0.676 −7.0 0.414 −3.6 0.503
Motor cortex 1.6 0.884 −4.7 0.468 1.8 0.845
Left piriform cortex −3.4 0.721 −11.0 0.078 −2.1 0.665
Right piriform cortex −5.6 0.572 −14.0 0.015 −1.5 0.725
Left somatosensory cortex 1.5 0.888 −11.1 0.198 0.0 0.996
Right somatosensory cortex −6.5 0.565 −10.3 0.329 0.3 0.973
Left substantia innominata −7.5 0.446 −14.2 0.141 −3.6 0.539
Right substantia innominata −6.7 0.502 −12.0 0.174 0.0 0.997
Hypothalamus −1.0 0.912 −4.3 0.460 4.0 0.363
Fig. 8. Variation map of gluCEST contrasts in WT littermate controls. Variation of gluCEST
contrasts wasmeasured in 8 ROIs between two groups ofWT littermate controls (n=4 in
each group).
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explained by their relatively young age of scanned mice (13 weeks),
whereas symptoms onset appears at 100 weeks or more (Menalled
et al., 2009). Consistent decreases in [Glu] and [Tau] were also reported
in Q111mice (Tkac et al., 2012) and in [Glu] in R6/2mice (Jenkins et al.,
2000, 2005).
Glutamate imaging
Changes in brain metabolites observed in HD patients and animal
models using MRS provide key insights about disease progression.
However, most MRS studies are focused on a speciﬁc brain region
which is supposed to be early affected in the disease. In the case of
HD, a wide majority of studies, including MRS or morphological chang-
es, were performed in the striatum. Nonetheless, recent studies have
shown than other brain regions such as the cortex or the corpus
callosum were also altered in HD and sometimes earlier than the stria-
tum (Zacharoff et al., 2012). GluCEST imaging offers the possibility to
map spatial distribution of Glu in the brain with a good spatial resolu-
tion, without a priori knowledge about the structures exhibiting most
important metabolic alterations. In this study, gluCEST images were
acquired with excellent anatomical resolution, allowing the accurate
delineation of several brain regions. While MRS requires rectangular
voxel, leadingmost of the time to partial volume effects, contamination
from surrounding structures was limited in gluCEST. The main advan-
tage of gluCEST imaging over MRS is highlighted in the variation maps
of glutamate levels calculated between WT littermates and heterozy-
gous mice and between WT littermates and homozygous mice.
To more speciﬁcally assess the reproducibility and precision of the
gluCEST measurement, we scanned eight additional WT mice, which
were randomly divided into two groups (WT1 and WT2). The variation
map of gluCEST contrasts calculated between WT1 and WT2 exhibited
small and non-signiﬁcant variations of gluCEST contrast (Fig. 8). Only
small variations of gluCEST contrast can be observed in some brain
structures (Table 1, right column) and were most likely due to noise
level in gluCEST images. The strongest decrease was measured in
the septal nuclei (−3.6% (p-value = 0.503)) whereas the strongest in-
crease was observed in the hypothalamus (+4.0% (p-value = 0.363)),
but no gluCEST variation was signiﬁcant. Hence, one can estimate that
a ±4% variation of gluCEST contrast corresponds to the detection
threshold of our method under the current experimental conditions.
This is much smaller than the signiﬁcant variations of gluCEST contrast
observed in HD mice, strongly reinforcing the validity of our results.
GluCEST contrast measured in HD mice was lower than in their
control littermates in almost all brain structures. As gluCEST contrast
is almost proportional to glutamate concentration at physiological
concentrations (Cai et al., 2012), it is safe to say that glutamateconcentration was decreased in HD mice. Moreover, glutamate loss
was more pronounced in homozygous as compared to heterozygous,
which is consistent with a faster progression of the disease in this latter
group. If striatumexhibited a decrease of glutamate concentration inHD
mice, and particularly a signiﬁcant decrease in homozygous mice
(−10.7% (p= 0.040) and−12.7% (p= 0.056) for left and right stria-
tum respectively), obvious variations were also measured in other
brain structures. The most striking result was the strong decrease of
gluCEST contrast in the corpus callosum observed in both heterozygous
and homozygous mice as compared to WT littermates (−21.8% (p =
0.033) and −28.4% (p = 0.030) respectively). Although corpus
callosum is not the most studied structure in the context of HD, some
previous studies have already demonstrated that this structure could
be altered. For instance, decrease of corpus callosum volume was
observed in two different mouse models (Lerch et al., 2008; Lerner
et al., 2012). Alterations of corpus callosum were also observed in HD
patients, notably using diffusion tensor imaging (DTI) (Rosas et al.,
2006, 2010; Weaver et al., 2009). These studies have demonstrated
thatwhitematter in pre- and early symptomatic HDpatientswas affect-
ed. They demonstrated that changes in diffusion parameters such as
fractional anisotropy (FA) and radial diffusivity (RD) were observed in
both pre-manifest and HD patients, whereas morphological changes of
corpus callosumoccurred only inHDpatients (Rosas et al., 2010).More-
over, changes in diffusion parameters were detectable several years
before changes in corpus callosum thickness, suggesting that alteration
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before neuronal death. The origin of topographical alteration of corpus
callosum was attributed to degeneration of particular cortical regions.
Indeed, corpus callosum is mainly composed by ﬁbers connecting left
and right hemispheres with axons projecting contra-laterally into the
cortex. In the present study, we demonstrated that corpus callosum
was the structure exhibiting the largest gluCEST variations in both HD
mice groups, indicating that the metabolic pool of glutamate was
decreased in those mice. Not expected at ﬁrst, such alterations of
metabolic pool of glutamate could reﬂect early changes in brain energy
metabolism and early compensatory mechanisms to maintain homeo-
stasis, and/or neuronal death. This ﬁnding seems consistent with previ-
ous studies suggesting a preferential vulnerability of corpus callosum in
the context of HD. This may also encourage carrying further studies in
order to precisely evaluate its alteration in other neurodegenerative
diseases (Teipel et al., 2002; Wiltshire et al., 2005).
We also noticed a decrease of gluCEST contrast in most cortex re-
gions, especially in homozygousmice, but not as signiﬁcant as in corpus
callosum. The larger decrease observed in the corpus callosummight be
explained by the fact that corpus callosum is a well-organized and
homogeneous structure. So, one can imagine that, if some neurons
were altered or suffering, their fraction in a given voxel would be
proportionally more important in the corpus callosum compared to a
voxel in a structure containing many cell types such as the striatum or
the cortex. However, pronounced decreases were observed in homozy-
gous mice in substantia innominata and piriform cortex. The decrease
was evenmore pronounced in this latter structure than in the striatum.
Interestingly, several previous studies performed on different mouse
models of HD demonstrated that neuronal plasticity was dramatically
altered in brain regions involved in olfactory tasks such as piriform
cortex (Lazic et al., 2007; van der Borght and Brundin, 2007). Moreover,
pioneer work performed on Ki140CAG model demonstrated that
htt protein aggregation was also important in the piriform cortex
(Menalled et al., 2003), suggesting potential olfactory impairments in
thosemice. Such deﬁcits in olfaction and especially in odors discrimina-
tion were observed in HD patients, even at early stage of the disease
(Lazic et al., 2007; Moberg et al., 1987). Our ﬁndings seem to corrobo-
rate that piriform cortex could be altered in this Ki140CAG mouse
model.
In the present study, we explored the potential of CEST imaging to
acquire glutamate distribution maps with a good spatial resolution.
Similarly toMRS, this is themetabolic pool of glutamatewhich is probed
using gluCEST imaging. However, both techniques are not strictly simi-
lar and should be compared with caution. First, comparison between
MRS and gluCEST is difﬁcult to perform in strictly identical regions of
interest, because signal localization and spatial resolutions are very
different in both cases. Furthermore, MRS offers a quantitative “direct”
detection of severalmetaboliteswhereas gluCEST is able to detect gluta-
mate through magnetization transfer between –NH2 protons and free
water protons. Several phenomena, such asmagnetic transfer asymme-
try or contribution of other exchanging protons from creatine or
gamma-aminobutyric acid, may compete with gluCEST contrast and
have a minor contribution to the gluCEST contrast (Cai et al., 2012).
Such undesirable effects can partially explain small differences between
our MRS and gluCEST results and further work will be needed in order
to precisely determine potential competing effects in this mouse
model. Nonetheless, gluCEST imaging remains a suitable technique to
map glutamate alteration levels at high resolution with few contamina-
tions of surrounding structures. Acquisition of a reliable spectrum using
MRS in small structures such as the corpus callosum would be much
more challenging. Chemical Shift Imaging, which offers an alternative
to map metabolic alterations in vivo, has also been proposed to study
HD rat models (Beal et al., 1993; Shemesh et al., 2010). However, if
the voxel size (a few μL) permitted by CSI was enough to study these
models with large excitotoxic lesions in rats, such resolution would
have been too large to detect subtle alterations in small brain structures,especially in mice. Therefore, the partial volume effect in gluCEST imag-
ing ismuch smaller than inMRSor CSI, giving probablymore reliable re-
sults in thin structures such as the corpus callosum. Of course, partial
volume effects below pixel resolution cannot be excluded, but this is a
general problem in imaging. However, since all structures surrounding
the corpus callosum appear to be less affected than the corpus callosum
itself (including potential partial volume effects), we must conclude
that partial volume effects can only result in an underestimation of
the gluCEST variation in the corpus callosum. In that context, the con-
clusions of the paper remain unchanged: the corpus callosum is indeed
themost affected structure, but the actual drop of gluCEST effect in pure
corpus callosum (far from the edge, excluding all potential partial
volume effects) may actually be slightly stronger that reported.
Recent studies have demonstrated the feasibility of gluCEST imaging
in healthy human brain and spinal cord (Cai et al., 2012, 2013; Kogan
et al., 2013) and also in patients with temporal lobe epilepsy (Davis
et al., 2015) at 7 T. In spite of SAR deposition limitations required for
safe human imaging and hardware restrictions of clinical scanner,
these studies showed the potential of gluCEST imaging to map with a
good resolution the actual glutamate distribution in brain and spinal
cord. The fast exchange regime of -NH2 protons requires high magnetic
ﬁelds (≥7 T), but the increasing availability of clinical 7 T scanners may
open the possibility to evaluate gluCEST imaging to monitor human HD
patients.
Conclusion
In this study, we used a knock-in mouse model of Huntington's
disease (Ki140CAG) in order to evaluate the interest of gluCEST imaging
as a relevant biomarker of HD. We demonstrated that gluCEST contrast
was decreased in most of brain regions in homozygous mice as
compared to their control littermates. The decrease was smaller in het-
erozygous mice brain which was consistent with a slower progression
of the disease in those mice. Atrophy and MRS-detected metabolic con-
tent of the striatum also displayed the same trend. All results indicated
modiﬁcation of metabolism in the brain of HD animal which might be
due to metabolic adaptation and/or defects. Interestingly, the good spa-
tial resolution offered by gluCEST imaging allowed identiﬁcation of
region-speciﬁc alterations. The corpus callosum seemed to be the
most affected brain structure in this mouse model, as largest gluCEST
contrast variations were measured in this region in both HD cohorts.
This result emphasizes the potential of gluCEST imaging for characteriz-
ing metabolic defects in neurodegenerative diseases in speciﬁc brain
regions. As gluCESTmethod has already been successfully implemented
on high-ﬁeld clinical scanners (Cai et al., 2013), its evaluation in
both pre-manifest and HD patients would be of high interest in order
to better understand the physiopathological pathways involving
glutamate in HD.
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